Abstract
In the following report, we describe a case of alkaline phosphatase (ALP) elevation occur-ring during treatment with alectinib (Alecensa™), which was administered for anaplastic lymphoma kinase (ALK) mutated metastatic non-small cell lung cancer (mNSCLC). A 51 year-old female with widespread metastatic disease exhibited a rapid and significant response within a very short period to alectinib therapy, accompanied by a rapid increase of ALP to more than six times the upper limit of normal (grade 3) ALP, decreasing to within normal limits within 3 weeks after initiation of therapy without any dose modification.
| Original language | English |
|---|---|
| Pages (from-to) | 173-177 |
| Number of pages | 5 |
| Journal | Current Oncology |
| Volume | 29 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1 Jan 2022 |
Keywords
- ALK mutation
- Alecensa® (Alectinib)
- Alkaline phosphatase (ALP)
- Lung adenocarcinoma
- Toxicity
ASJC Scopus subject areas
- Oncology
